The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Novel PET Tracer Development Program, 2022Screening for PET Tracers that will Bind to the P2Y12 Receptor and Allow Monitoring of Microglia Activation During Neuroinflammation
Study Rationale: One of the hallmarks of Parkinson’s disease (PD) is neuroinflammation. During this dynamic process, the brain’s immune cells, called microglia, become activated and can either prolong...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2022Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease
Study Rationale: Mutations in GBA1, the gene that encodes glucocerebrosidase (GCase), diminish GCase activity in an estimated 7 to 10% of people with Parkinson’s disease (PD). In addition, reduced...
-
Research Grant, 2022Parkinson’s Disease Treatment Evaluation and Access Strategy: Phase 1
Study Rationale: Core funding programs at The Michael J. Fox Foundation (MJFF) have historically focused on research to understand, measure, and treat Parkinson’s disease (PD). MJFF is now seeking to...
-
Biomarkers to Support Therapeutic Trials Program, 2022Identifying Biomarkers for a Mitochondrial Subtype of Parkinson’s Disease
Study Rationale: Increasing evidence suggests that the disorder we refer to as Parkinson’s disease (PD) might represent several diseases, each driven by different biological mechanisms. The...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2022Advancing Biological Understanding of PINK1 and Parkin Rodent Models of Parkinson’s Disease
Study Rationale: Although loss-of-function mutations in the PINK1 and Parkin genes are known to cause early onset Parkinson’s disease (PD), the cellular and molecular mechanisms remain uncertain. We...
-
Translational Pipeline Program, 2022Prevention of Dementia in GBA-associated Parkinson’s Disease
Study Rationale: Whereas motor symptoms can be well controlled by dopamine-enhancing drugs and deep brain stimulation, dementia represents a key milestone in the course of Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.